Valeant is buying Sprout Pharma, the company that has been given the go ahead for a drug that increases women’s libido.
The Vetr crowd already has their stock predicted at $279.50 while the analysts are at a sell on this. Perhaps Sprout could could share some of it’s compound with this Wall Street community.